- Home
- RY vs NVO Comparison
RY vs NVO Comparison
Compare RY & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RY | NVO |
|---|---|---|
| Founded | 1864 | 1923 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RY | NVO |
|---|---|---|
| Price | $165.16 | $48.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $162.00 | $54.25 |
| AVG Volume (30 Days) | 1.1M | ★ 18.3M |
| Earning Date | 12-03-2025 | 02-04-2026 |
| Dividend Yield | ★ 2.60% | 2.51% |
| EPS Growth | ★ 25.07 | 10.06 |
| EPS | ★ 10.04 | 3.67 |
| Revenue | $44,415,504,717.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $12.73 | $7.77 |
| Revenue Next Year | $4.01 | $1.86 |
| P/E Ratio | $16.57 | ★ $13.36 |
| Revenue Growth | 15.03 | ★ 16.64 |
| 52 Week Low | $106.10 | $43.08 |
| 52 Week High | $167.91 | $109.88 |
Technical Indicators
Market Signals| Indicator | RY | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 72.10 | 45.72 |
| Support Level | $152.51 | $46.08 |
| Resistance Level | $167.91 | $50.75 |
| Average True Range (ATR) | 2.20 | 1.09 |
| MACD | 0.58 | 0.32 |
| Stochastic Oscillator | 81.95 | 38.65 |
Price Performance
Historical ComparisonAbout RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.